Evolving ideas on non-alcoholic fatty liver disease: from risk to catastrophe
DOI:
https://doi.org/10.14739/2310-1210.2020.2.200637Keywords:
non-alcoholic fatty liver disease, fatty liver, steatohepatitis, clinic, diagnosis, treatment, comorbidityAbstract
The aim of the work is to study the development of non-alcoholic fatty liver disease (NAFLD) accompanied by changes in the clinical course and general transformation of diagnostic and therapeutic approaches to a patient with comorbid conditions.
Materials and methods. A retrospective and prospective analysis of the specialized literature and research on NAFLD associated with comorbid clinical conditions was carried out.
Results. The review of the scientific literature provides data on the development of NAFLD associated with comorbidity, the results of clinical studies, as well as own observations. The main causes and risk factors, pathogenesis, prevalence and course of NAFLD, which is a hepatic manifestation of metabolic syndrome, are discussed. The criteria for NAFLD diagnosis, diagnostic capabilities of various invasive and non-invasive methods, and modern approaches to the management of patients are presented. It has been shown that modern NAFLD treatment should take into account all existing risk factors including lifestyle modification, implications for metabolic syndrome components, hepatoprotective therapy, and correction of the intestinal microbiota.
Conclusions. NAFLD in modern conditions is one of the most common diseases among the Ukrainian population in the overall structure of the internal organ pathology. Insufficient information on the features of NAFLD comorbid course limits the possibilities of diagnosis and treatment for this category of patients. Thus, the history of the development, progression and treatment of NAFLD comorbid course is constantly being improved.
References
Bazylevych, A. Ya. (2015). Nealkoholnyi steatohepatyt yak novyi faktor rozvytku ishemichnoi khvoroby sertsia [Non-alcoholic steatohepatitis as a new factor of developing ischaemic heart disease]. ScienceRise, (10), 171-175. https://doi.org/10.15587/2313-8416.2015.52369 [in Ukrainian].
Nabieva, D. A. (2017). Immunologicheskie mekhanizmy razvitiya nealkogol'noi zhirovoi bolezni pecheni u bol'nykh podagroi i psevdopodagroi: obzor literatury [Immunological mechanisms for the development of nonalcoholic fatty liver disease in patients with gout and pseudogout: a review of literature]. Nauchno-prakticheskaya revmatologiya, 55(5), 560-565. https://doi.org/10.14412/1995-4484-2017-560-565 [in Russian].
Pal'gova, L. K. (2014). Geneticheskie faktory patogeneza nealkogol'noi zhirovoi bolezni pecheni: fundamental'nye i prikladnye aspekty. Est' li puti resheniya? [Genetic factors in the pathogenesis of non-alcoholic fatty liver disease: fundamental and applied aspects. Are there any solutions?]. Consilium Medicum. Gastroenterologiya, (1),18-23. [in Russian].
Rozumbaeva, L. P., Kozlova, I. V., Bykova, A. P., Safonova, M. V., & Pakhomova, A. L. (2014). Patologiya gepatobiliarnoy sistemy i psoriaz: vzaimosvyazi i vzaimovliyaniya [Psoriasis and pathology of the hepatobiliary system: the relationship and mutual influence]. Sovremennye problemy nauki i obrazovaniya, (4). [in Russian]. http://www.science-education.ru/ru/article/view?id=14105.
Stepanov, Yu. M., & Filippova, A. Yu. (2006). Klinicheskie osobennosti techeniya nealkogol'nogo steatogepatita v zavisimosti ot soputstvuyushchikh zabolevanii [Peculiarities of the clinical course of nonxalcoholic steatohepatitis depending on concomitant diseases]. Suchasna hastroenterolohiia, (3), 4-7. http://www.vitapol.com.ua/user_files/pdfs/gastro/337868311858671_15062009105858.pdf. [in Russian].
Stepanov, Yu. M., & Filippova, О. Yu. (2016). Osoblyvosti zmin pokaznykiv T- ta V-klitynnoho imunitetu zalezhno vid indeksu masy tila u patsiientiv z nealkoholnoiu zhyrovoiu khvoroboiu pechinky u poiednanni z ozhyrinniam i patolohiieiu biliarnoho traktu [The features of the changes of T- and B-cell immunity depending on the body mass index in the patients with the nonalcoholic fatty liver disease in combination with the obesity and the pathology of biliary tract]. Ukrainskyi terapevtychnyi zhurnal, (4), 46-54. http://www.vitapol.com.ua/user_files/pdfs/utj/utj51i08iutj4-16.pdf. [in Ukrainian].
Stepanov, Yu. M., & Filippova, A. Yu. (2017). Morfolohichni osnovy otsinky steatozu, steatohepatytu ta fibrozu u khvorykh na nealkoholnu zhyrovu khvorobu pechinky v poiednanni z ozhyrinniam i patolohiieiu biliarnoho traktu [Morphological basis for the assessment of steatosis, steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease associated with obesity and pathology of the biliary tract]. Hastroenterologia, 51(3), 196-204. https://doi.org/10.22141/2308-2097.51.3.2017.112636 [in Ukrainian].
Filippova, A. Yu. (2016). Nadlyshkova masa tila i ozhyrinnia yak prychyna prohresuvannia endohennoi intoksykatsii u patsiientiv z nealkoholnoiu zhyrovoiu khvoroboiu pechinky [Excessive body mass and obesity as a cause of progression of endogenous intoxication in patients with non-alcoholic fatty liver disease]. Zaporozhye medical journal, (3), 63-66. https://doi.org/10.14739/2310-1210.2016.3.76985 [in Ukrainian].
Filippova, A. Yu. (2016). Klinichna kharakterystyka khvorykh na steatoz pechinky ta nealkoholnyi steatohepatyt u poiednanni z ozhyrinniam i patolohiieiu biliarnoho traktu zalezhno vid indeksu masy tila [Clinical characteristics of patients with hepatic steatosis and non-alcoholic steatohepatitis, combined with obesity and disorders of the biliary tract, depending on the body mass index]. Medychni perspektyvy, 21(1), 70-79. [in Ukrainian].
Filippova, A. Yu. (2017). Dynamika antropometrychnykh i biokhimichnykh pokaznykiv pid vplyvom riznykh skhem likuvannia u khvorykh na nealkoholnu zhyrovu khvorobu pechinky u poiednanni z ozhyrinniam i patolohiieiu biliarnoho traktu [Dynamics of anthropometric and biochemical parameters under the influence of different treatment regimens in patients with non-alcoholic fatty liver disease in combination with obesity and pathology of the biliary tract]. Likarska sprava, (5-6), 54-61. [in Ukrainian].
Bao, Y. (Bao, Y.). The progress of studying the mechanisms of immune cells in the regulation of non-alcoholic fatty liver diseases. Zhonghua gan zang bing za zhi, 25(7), 553-556. https://doi.org/10.3760/cma.j.issn.1007-3418.2017.07.018 [in Chinese].
Cani, P. D., Everard, A., & Duparc, T. (2013). Gut microbiota, enteroendocrine functions and metabolism. Current Opinion in Pharmacology, 13(6), 935-940. https://doi.org/10.1016/j.coph.2013.09.008
Della Corte, C., Mazzotta, A. R., & Nobili, V. (2016). Fatty liver disease and obesity in youth. Current Opinion in Endocrinology & Diabetes and Obesity, 23(1), 66-71. https://doi.org/10.1097/med.0000000000000221
Grechanyk, M. M., Grechanyk, N. M., Filippova, A. J., & Kuryata, A. V. (2016). Endothelial dysfunction, level of leptin and body mass index in patient with coronary heart disease with preserved systolic function in combination with hepatic steatosis. European Journal of Heart Failure, 18(Suppl. 1), 273. https://onlinelibrary.wiley.com/toc/18790844/18/S1
Filippova, O. Yu. (2016). Imbalance of the Humoral Component of the Immune System as a Basis for the Progression of Non-Alcoholic Fatty Liver Disease in Patients with Obesity and Concomitant Biliary Tract Pathology. Arkhiv klinichnoi medytsyny, (2), 43-47. https://doi.org/10.21802/acm.2016.2.9
Grechanyk, N., Filippova, A., & Kuryata, A. (2016). Endotelial dysfunction, blood lipid spectrum, level of leptin and mass of body in patient with coronary heart disease in combination with hepatic steatosis. Atherosclerosis, 252, Article e161. https://doi.org/10.1016/j.atherosclerosis.2016.07.774
Ludwig, J., Viggiano, T. R., McGill, D. B., & Oh, B. J. (1980). Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clinic Proceedings, 55(7), 434-438.
Manne, V., Handa, P., & Kowdley, K. V. (2018). Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Clinics in Liver Disease, 22(1), 23-37. https://doi.org/10.1016/j.cld.2017.08.007
Lonardo, A., Ballestri, S., Marchesini, G., Angulo, P., & Loria, P. (2015). Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome. Digestive and Liver Disease, 47(3), 181-190. https://doi.org/10.1016/j.dld.2014.09.020
L’Hermitte, A., Pham, S., Cadoux, M., & Couty, J.-P. (2016). Non alcoholic-fatty liver disease causes selective CD4+ T lymphocytes loss and promotes hepatocarcinogenesis. Medecine Sciences (Paris), 32(11), 1023-1026. https://doi.org/10.1051/medsci/20163211021 [in French].
Spahis, S., Delvin, E., Borys, J.-M., & Levy, E. (2017). Oxidative Stress as a Critical Factor in Nonalcoholic Fatty Liver Disease Pathogenesis. Antioxidants & Redox Signaling, 26(10), 519-541. https://doi.org/10.1089/ars.2016.6776
Ray, I., Bhattacharya, A., & De, R. K. (2017). OCDD: an obesity and co-morbid disease database. BioData Mining, 10, Article 33. https://doi.org/10.1186/s13040-017-0153-5
Lee, S.-W., Lee, T.-Y., Yang, S.-S., Tung, C.-F., Yeh, H.-Z., & Chang, C.-S. (2018). Risk factors and metabolic abnormality of patients with non-alcoholic fatty liver disease: Either non-obese or obese Chinese population. Hepatobiliary & Pancreatic Diseases International, 17(1), 45-48. https://doi.org/10.1016/j.hbpd.2018.01.007
Sookoian, S., & Pirola, C. J. (2011). Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology, 53(6), 1883-1894. https://doi.org/10.1002/hep.24283
Reardon, J., Hussaini, T., Alsahafi, M., Azalgara, V. M., Erb, S. R., Partovi, N., & Yoshida, E. M. (2016). Ursodeoxycholic acid in treatment of non-cholestatic liver diseases: A systematic review. Journal of Clinical and Translational Hepatology, 4(3), 192-205. https://doi.org/10.14218/jcth.2016.00023
Valenti, L., Alisi, A., & Nobili, V. (2012). I148M PNPLA3 variant and progressive liver disease: a new paradigm in hepatology. Hepatology, 56(2), 1883-1889.
Westwater, J. O., & Fainer, D. (1958). Liver impairment in the obese. Gastroenterology, 34(4), 686-693.
World Health Organization. (2020, March 3). Obesity and overweight. http://www.who.int/mediacentre/factsheets/fs311/en/.
Zelman, S. (1952). The liver in obesity. Archives of Internal Medicine, 90(2), 141-156. https://doi.org/10.1001/archinte.1952.00240080007002
Zhang, Q. Q., & Lu, L. G. (2015). Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment Strategy. Journal of Clinical and Translational Hepatology, 3(1), 78-84. https://doi.org/10.14218/jcth.2014.00037
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
